ClinicalTrials.gg
CompletedNCT05536297Updated May 18, 2026Results posted

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

A Phase 3 interventional study of avacincaptad pegol in Geographic Atrophy and Age-Related Macular Degeneration, sponsored by Astellas Pharma Global Development, Inc.. Completed at 117 sites in 17 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
278
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Enrollment
29th of 107
278 · median 98
Started
2022
with 4 others
Phase 3
15 of 131
2 open now
Registered
84th of 131
by date

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 29th largest by enrollment of the 107 interventional ones that give a count, is one of 5 that started in 2022, is one of 15 in phase 3, and was the 84th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 23 visit on study treatment (either avacincaptad pegol or Sham).

03

Conditions studied

  • Geographic Atrophy
  • Age-Related Macular Degeneration

Keywords

  • Geographic Atrophy;
  • Macular Degeneration;
  • ARC1905;
  • Avacincaptad pegol;
  • Zimura (previous name);
  • Izervay
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged 50 years or greater diagnosed with GA inside and/or outside of the fovea who completed Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment.
  • Patient must provide new written for this OLE trial prior to participation.
  • Patient must have the ability to return for all trial visits for the duration of the 18-month trial.

Exclusion criteria

Exclusion Criteria:

  • Patient did not complete Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment (either avacincaptad pegol or Sham).
  • Patient who had the study drug permanently withdrawn for an AE during ISEE2008 are not eligible.
  • Patient did not enroll into this OLE trial within the 90 day enrollment period.
  • Patient who is pregnant or nursing.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
278 participants (actual)

Study arms

  • Experimental
    avacincaptad pegol

    Participants will receive avacincaptad pegol 2 mg monthly from Month 1 to Month 17.

    Drug: avacincaptad pegol

Interventions

  • Intravitreal Injection

    Also known as: Zimura (previous name), ARC1905, Izervay

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a participant including unfavorable and unintended signs, symptoms or disease temporally associated with the use of a medicinal product and which does not necessarily have to have a causal relationship to this treatment. AEs include illnesses with onset during the trial, or exacerbations of pre-existing illnesses. Exacerbation of pre-existing illness is defined as a significant increase in the severity of the illness as compared to the start of the trial and was considered when a participant requires new or additional treatment for that illness. Lack of or insufficient clinical response or efficacy was not recorded as an AE.

    Time frame: Up to 18 months

Secondary outcomes

  1. Number of Participants With Anti-drug Antibody (ADA)

    Number of participants with ADA = Post-baseline positive (in Baseline negative group) + treatment-boosted ADA positive (in Baseline positive group) / participants with a Baseline and at least one post-baseline sample. For participants whose ADA status is positive at Baseline, a post-baseline titer value that is \>= 4 times higher than the Baseline is considered treatment-boosted ADA.

    Time frame: Up to 18 months

  2. Plasma Concentrations of ACP

    Concentrations below the lower limit of quantification (3.36 ng/mL) are set to zero for calculation of summary statistics.

    Time frame: Months 1, 2, 4, 7, 13, and 18

07

Results

Posted Apr 14, 2026

Participant flow

Participants who completed study ISEE2008 (NCT04435366; GATHER2) through the Month 23 visit on assigned treatment (avacincaptad pegol \[ACP\] or sham) were enrolled in the study.

Participant flow — Overall Study
MilestoneACP Every Month (EM) to ACP EMACP EM/Every Other Month (EOM) to ACP EMSham to ACP EM
Started6462152
Completed5654127
Not completed8825
Withdrew: Adverse event137
Withdrew: Other102
Withdrew: Death011
Withdrew: Participant request5210
Withdrew: Sponsor decision102
Withdrew: Investigator decision001
Withdrew: Lost to follow-up022

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

An AE is defined as any untoward medical occurrence in a participant including unfavorable and unintended signs, symptoms or disease temporally associated with the use of a medicinal product and which does not necessarily have to have a causal relationship to this treatment. AEs include illnesses with onset during the trial, or exacerbations of pre-existing illnesses. Exacerbation of pre-existing illness is defined as a significant increase in the severity of the illness as compared to the start of the trial and was considered when a participant requires new or additional treatment for that illness. Lack of or insufficient clinical response or efficacy was not recorded as an AE.

Time frame:
Up to 18 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsACP EM to ACP EMACP EM/EOM to ACP EMSham to ACP EM
Number of Participants With Adverse Events (AEs)5049129
SecondaryNumber of Participants With Anti-drug Antibody (ADA)

Number of participants with ADA = Post-baseline positive (in Baseline negative group) + treatment-boosted ADA positive (in Baseline positive group) / participants with a Baseline and at least one post-baseline sample. For participants whose ADA status is positive at Baseline, a post-baseline titer value that is \>= 4 times higher than the Baseline is considered treatment-boosted ADA.

Time frame:
Up to 18 months
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibody (ADA)
ParticipantsACP EM to ACP EMACP EM/EOM to ACP EMSham to ACP EM
Number of Participants With Anti-drug Antibody (ADA)102
SecondaryPlasma Concentrations of ACP

Concentrations below the lower limit of quantification (3.36 ng/mL) are set to zero for calculation of summary statistics.

Time frame:
Months 1, 2, 4, 7, 13, and 18
Reported as:
Mean · ng/mL
Plasma Concentrations of ACP
ng/mLACP EM to ACP EMACP EM/EOM to ACP EMSham to ACP EM
Month 19.17 ± 20.95.97 ± 13.90.0440 ± 0.537
Month 235.6 ± 21.831.7 ± 24.431.9 ± 19.3
Month 441.1 ± 28.337.8 ± 38.334.6 ± 23.3
Month 733.7 ± 27.330.0 ± 23.137.5 ± 30.8
Month 1344.8 ± 29.834.4 ± 29.436.0 ± 29.3
Month 1842.3 ± 33.738.7 ± 30.233.9 ± 30.1

Adverse events

Collected over All-cause mortality: From randomization up to 18 months. AEs: From first dose of study drug up to 18 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ACP EM to ACP EM0/64 (0%)14/64 (21.9%)42/64 (65.6%)
ACPEM/EOM to ACP EM2/62 (3.2%)13/61 (21.3%)39/61 (63.9%)
Sham to ACP EM3/152 (2%)24/151 (15.9%)93/151 (61.6%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventACP EM to ACP EMACPEM/EOM to ACP EMSham to ACP EM
Acute myocardial infarctionCardiac disorders0/641/610/151
Atrial fibrillationCardiac disorders0/641/610/151
Cardiac failureCardiac disorders0/641/610/151
Cardio-respiratory arrestCardiac disorders0/641/610/151
CataractEye disorders0/641/610/151
ColitisGastrointestinal disorders0/641/610/151
Large intestine polypGastrointestinal disorders0/641/610/151
Device related infectionInfections and infestations0/641/610/151
PneumoniaInfections and infestations1/641/611/151
Femoral neck fractureInjury, poisoning and procedural complications0/641/610/151
Most frequent other events
Showing 10 of 15
Most frequent other events
EventACP EM to ACP EMACPEM/EOM to ACP EMSham to ACP EM
CataractEye disorders6/6410/6114/151
Intraocular pressure increasedInvestigations9/6410/6121/151
Choroidal neovascularisationEye disorders10/643/6120/151
FallInjury, poisoning and procedural complications9/644/6112/151
COVID-19Infections and infestations8/645/619/151
Visual acuity reducedEye disorders4/643/6118/151
Conjunctival haemorrhageEye disorders7/646/6117/151
Urinary tract infectionInfections and infestations5/642/6111/151
Vitreous detachmentEye disorders4/644/613/151
BronchitisInfections and infestations2/644/613/151

Baseline characteristics

Full Analysis Set (FAS) included all enrolled participants.

Age, Continuous
Age, Continuous(years)ACP EM to ACP EMACP EM/EOM to ACP EMSham to ACP EMTotal
Mean75.9 ± 9.378.6 ± 8.177.9 ± 8.477.6 ± 8.6
Age, Customized
Age, Customized(Participants)ACP EM to ACP EMACP EM/EOM to ACP EMSham to ACP EMTotal
In Utero0000
Pre-term newborn - gestational age < 37 wk0000
Newborns (0-27 days)0000
Infants and toddlers (28 days-23 months)0000
Children (2-11 years)0000
Adolescents (12-17 years)0000
Adults (18-64 years)931123
Elderly (From 65-84 years)4441108193
Elderly 85 years and over11183362
Sex: Female, Male
Sex: Female, Male(Participants)ACP EM to ACP EMACP EM/EOM to ACP EMSham to ACP EMTotal
Female4638105189
Male18244789
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ACP EM to ACP EMACP EM/EOM to ACP EMSham to ACP EMTotal
Hispanic or Latino54716
Not Hispanic or Latino5245126223
Unknown or Not Reported7131939
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ACP EM to ACP EMACP EM/EOM to ACP EMSham to ACP EMTotal
White5747130234
Black or African American0011
Asian0011
American Indian or Alaska Native0000
Native Hawaiian or Other Pacific Islander0000
Other0213
Not Reported7131939
Unknown0000
08

Study locations

117 sites
  • Retinal Diagnostic Center
    Campbell, California 95008, United States
  • Eye Medical Center of Fresno
    Fresno, California 93720, United States
  • Retina Consultants of Orange County
    Fullerton, California 92835, United States
  • Jacobs Retina Center at The Shiley Eye Institute USCD
    La Jolla, California 92093, United States
  • Jules Stein Eye Institute David Geffen School of Medicine
    Los Angeles, California 90095, United States
  • Doheny Eye Center, UCLA
    Pasadena, California 91105, United States
  • Retina Consultants of Southern California
    Redlands, California 92374, United States
  • Orange County Retinal Med Group
    Santa Ana, California 92705, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Retina Consultants of Southern CO
    Colorado Springs, Colorado 80909, United States
  • Colorado Retina Associates, PC
    Lakewood, Colorado 80228, United States
  • Rand Eye Institute
    Deerfield Beach, Florida 33064, United States
  • Retina Group of Florida
    Fort Lauderdale, Florida 33308, United States
  • Florida Eye Associates
    Melbourne, Florida 32901, United States
  • Retina Care Specialists
    Palm Beach Gardens, Florida 33410, United States
  • Retina Associates of Sarasota
    Sarasota, Florida 34233, United States
  • Retina Vitreous Associates of Florida
    St. Petersburg, Florida 33711, United States
  • East Florida Eye Institute
    Stuart, Florida 34994, United States
  • Southern Vitreoretinal Associates
    Tallahassee, Florida 32308, United States
  • Center for Retina & Macula Disease
    Winter Haven, Florida 33880, United States
  • Southeast Retina Center P.C.
    Augusta, Georgia 30909, United States
  • Retina Consultants of Hawaii, Inc.
    ‘Aiea, Hawaii 96701, United States
  • Illinois Eye Center
    Peoria, Illinois 61615, United States
  • Vitreo Retinal Consultants & Surgeons
    Wichita, Kansas 67214, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70124, United States
  • The Retina Group of Washington
    Chevy Chase, Maryland 20815, United States
  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21740, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • Retina Research Institute at New England Retina
    Springfield, Massachusetts 01107, United States
  • Vitreoretinal Associates PC
    Worcester, Massachusetts 01605, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • Retina Vitreous Surgeons of Central New York
    Liverpool, New York 13088, United States
  • Ophthalmic Consultants of Long Island
    Oceanside, New York 11572, United States
  • Retina Associates of Western NY
    Rochester, New York 14620, United States
  • Western Carolina Retinal Associates
    Asheville, North Carolina 28803, United States
  • Retina & Vitreous Center of Southern Oregon, PC
    Ashland, Oregon 97520, United States
  • Retina Northwest PC
    Portland, Oregon 97221, United States
  • Eye Health Northwest
    Portland, Oregon 97225, United States
  • Mid Atlantic Retina - Wills Eye Institute
    Philadelphia, Pennsylvania 19107, United States
  • Associates in Ophthalmology
    West Mifflin, Pennsylvania 15122, United States
  • Retina Research of Beaufort
    Beaufort, South Carolina 29902, United States
  • Palmetto Retina Center
    West Columbia, South Carolina 29169, United States
  • Black Hills Regional Eye Institute
    Rapid City, South Dakota 57701, United States
  • Southeastern Retina Associates, PC
    Knoxville, Tennessee 37922, United States
  • Retina Research Institute of Texas, LLC
    Abilene, Texas 79606, United States
  • Southwest Retina Specialists
    Amarillo, Texas 79106, United States
  • Austin Retina Associates
    Austin, Texas 78705, United States
  • Retina Foundation of the Southwest
    Dallas, Texas 75231, United States
  • Retina Center of Texas
    Southlake, Texas 76092, United States
  • Retina Consultants of Houston
    The Woodlands, Texas 77384, United States
  • Strategic Clinical Research Group, LLC
    Willow Park, Texas 76087, United States
  • Retina Associates of Utah PC
    Salt Lake City, Utah 84107, United States
  • Pacific Northwest Retina
    Bellevue, Washington 98004, United States
  • Oftalmólogos Especialistas
    Rosario, Sante Fe S2000ANJ, Argentina
  • Centro Oftalmológico Dr. Charles
    Buenos Aires, 1116, Argentina
  • Instituto Oftalmologico de Buenos Aires
    Buenos Aires, 1830, Argentina
  • Oftar Mendoza
    Mendoza, 5500, Argentina
  • Microcirugia Ocular
    Santa Fe, Argentina
  • Centre for Eye Research Australia
    East Melbourne, 3002, Australia
  • Sydney Retina Clinic
    Sydney, 2000, Australia
  • Medizinische Universitat Graz
    Styria, 8036, Austria
  • Medizinische Universitat Innsbruck
    Tyrol, 6020, Austria
  • Medical University of Vienna, Department of Ophthalmology and Optometry
    Vienna, 1090, Austria
  • Centre H. U. Brugmann
    Brussels, 1020, Belgium
  • Centro de Ensino e Pesquisa do Instituto de Visao
    Belo Horizonte, 30330-00, Brazil
  • Universidade Federal de Sao Paulo
    São Paulo, 04023-062, Brazil
  • IPEPO - Instituto da Visao
    São Paulo, 04038-032, Brazil
  • Calgary Retina Consultants
    Calgary, Alberta T2H 0C8, Canada
  • St. Joseph's Health Care London
    London, Ontario N6A4V2, Canada
  • Retina Centre of Ottawa
    Ottawa, Ontario K2B 7E9, Canada
  • Fundacion Oftalmologica Nacional
    Bogotá, 110231, Colombia
  • Clinica de Oftalmologia Sandiego
    Medellín, 00000, Colombia
  • Clinical Hospital Osiiek, Ophthalmology Clinic
    Osijek, 31000, Croatia
  • Lékárna nad Knížecí Kováků
    Smíchov, 150 00, Czechia
  • University Hospital of Bordeaux
    Bordeaux, 33000, France
  • Hopital Intercommunal de Creteil
    Créteil, 94010, France
  • Pole Vision Val D'Ouest
    Écully, 69130, France
  • Centre Ophtalmologique Rabelais
    Lyon, 69002, France
  • Hopital de la Croix-Rousse
    Lyon, 69317, France
  • Centre Paradis-Monticelli
    Marseille, 13008, France
  • Centre D'exploration Ophtalmologique De L'odéon
    Paris, 75006, France
  • Centre d'Imagerie et Laser
    Paris, 75015, France
  • Rothschild Foundation
    Paris, 75019, France
  • Hopital Lariboisiere, Service Pharmacie
    Paris, 75745, France
  • Centre Ophtalmologique Saint Exupéry
    Saint-Cyr-sur-Loire, 37540, France
  • Universitätsklinikum Hamburg Eppendorf
    Hamburg, 20251, Germany
  • Universitätsklinik für Augenheilkunde, Medizinische Hochschule Hannover
    Hanover, 30625, Germany
  • Augenklinik der Ludwig-Maximilian Universität München
    München, 80336, Germany
  • Eye Clinic Ludwig Maximilian
    München, 80336, Germany
  • Augenzentrum am St. Franziskus-Hospital
    Münster, 48145, Germany
  • Dept. of Ophthalmology Semmelweis University Budapest
    Budapest, 1085, Hungary
  • Bajcsy Zsilinszky Korhaz Szemeszet
    Budapest, 1106, Hungary
  • Budapest Retina Associates
    Budapest, 1133, Hungary
  • Barzilai Medical Center
    Ashkelon, 7830604, Israel
  • Carmel Medical Center
    Haifa, 3436212, Israel
  • Kaplan Medical Center
    Rehovot, 94410606, Israel
  • Shamir Medical Center
    Tzrifin, 70300, Israel
  • AOU Policlinico S. Orsola-Malpighi
    Bologna, 40138, Italy
  • Clinica Oftalmologica Ospedale C. S.S. Annunziata
    Chieti, 66100, Italy
  • Ospedaliero Universitaria di Ferrara
    Ferrara, 44124, Italy

Showing the first 100 of 117 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Apr 2025, 30 months.

Results were first posted in Apr 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2022
First posted
Sep 10, 2022
StartActual
Sep 26, 2022
Primary completionActual
Apr 10, 2025
CompletionActual
Apr 10, 2025
Results first posted
Apr 14, 2026
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05536297
Responsible party
Sponsor
First posted
Sep 10, 2022
Start date
Sep 26, 2022
Primary completion
Apr 10, 2025
Completion
Apr 10, 2025
Results posted
Apr 14, 2026
Last update
May 18, 2026

Study contacts

Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avacincaptad pegol

Start the discussion